Conmed (CNMD) Cash from Financing Activities (2010 - 2026)

Conmed (CNMD) has 17 years of Cash from Financing Activities data on file, last reported at -$46.2 million in Q2 2026.

• Quarterly Cash from Financing Activities fell 74.29% year-over-year to -$46.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$149.7 million (down 3.35% YoY) and the FY2025 annual result came in at -$135.8 million, up 10.05% from the prior year.
• Cash from Financing Activities slipped to -$46.2 million in Q2 2026, from -$22.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $159.1 million in Q2 2022 to a low of -$58.8 million in Q4 2023.
• A 5-year average of -$13.4 million and a median of -$27.5 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 820.17% — and 2023, when it slumped 610.34%.
• Tracing CNMD's Cash from Financing Activities over 5 years: stood at $11.5 million in 2022, then tumbled by 610.34% to -$58.8 million in 2023, then rose by 13.1% to -$51.1 million in 2024, then climbed by 26.83% to -$37.4 million in 2025, then slipped by 23.72% to -$46.2 million in 2026.
• The last three Cash from Financing Activities figures came in at -$46.2 million (Q2 2026), -$22.6 million (Q1 2026), and -$37.4 million (Q4 2025), per Business Quant data.